1. Scrip
  2. >>Conferences
  3. >>J.P. Morgan

JPM 2025: Deals, Politics And Parties To Welcome A New Year For Pharma

 
• By Jessica Merrill

Politics and policy may get as much attention as deals at the J.P. Morgan Healthcare conference, as this year’s meeting comes just before the inauguration of Donald Trump as US president.

(Shutterstock)
Key Takeaways

The J.P. Morgan Healthcare conference, viewed as a barometer by which to test the health of the pharmaceutical industry for the year ahead, will run 12-16 January.

US politics and policy are likely to be big themes at this year’s meeting, with Donald Trump poised to be inaugurated as US president days after the meeting wraps.

Deal news is the big draw at J.P. Morgan and it remains to be seen if 2025 will top the various bolt-on deals that were announced in 2024.

It was eight years ago during the J.P. Morgan Healthcare conference that Donald Trump accused pharmaceutical manufacturers of “getting away with murder,” just days before being inaugurated US president the first time in 2017

Now drug makers are wondering which Trump will return to the White House following his reelection – a friend to pharma or agitator – and what the new administration will have in store for industry

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By Mandy Jackson

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By Mandy Jackson

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 
• By Jessica Merrill

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Conferences

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By Kevin Grogan

The UK giant is forecasting peak sales of $5bn plus

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.